Company intelligence / Profile preview
BioRestorative Therapies
Melville, New York, United Statesbiorestorative.com ↗
- Ownership
- Public · BRTX
- Development stage
- Other
01
Overview
BRTX-100 has received FDA Fast Track designation for chronic lumbar disc disease. Phase 2 clinical trial is ongoing with positive safety data reported. No serious adverse events have occurred in the trial. The FDA has also cleared an IND for a Phase 2 trial of BRTX-100 for chronic cervical discogenic pain.
- Therapeutic areas
- EndocrinologyNeurology
- Modalities
- Stem cell therapiesCell-based therapeuticsTissue protocols
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Financials
- Market cap
- $2.1M
- Total revenue
- $359.7K
- Enterprise value
- $-1.5M
Beyond the preview
Go deeper on BioRestorative Therapies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioRestorative Therapies.